Drug Database · Clinicians

Mannitol

Brands (6) A.N.B. Mannitol, Axatol-20, Diuretol…Show all

Osmotic Diuretic (Osmotic Activity) US FDA class
Osmotic diuretic agent; Diuretic; and others PH FDA category

Rx · Prescription drug13 PH productsPNF-listedVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 8ad3145e-00e7-4412-b9a5-06f00f264f30, version date April 21, 2026 (Mannitol · Hospira, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • intracranial pressure and treatment of cerebral edema.
  • elevated intraocular pressure.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Mannitol Injection is indicated for the reduction of: • intracranial pressure and treatment of cerebral edema. • elevated intraocular pressure. Mannitol Injection is an osmotic diuretic, indicated for the reduction of: • intracranial pressure and treatment of cerebral edema. (1) • elevated intraocular pressure. (1)

Contraindications

4 CONTRAINDICATIONS Mannitol Injection is contraindicated in patients with:

  • Known hypersensitivity to mannitol [see Warnings and Precautions (5.1)].
  • Anuria [see Warnings and Precautions (5.2)].
  • Severe hypovolemia [see Warnings and Precautions (5.4)].
  • Pre-existing severe pulmonary vascular congestion or pulmonary edema [see Warnings and Precautions (5.5)].
  • Active intracranial bleeding except during craniotomy.
  • Known hypersensitivity to mannitol. (4, 5.1)
  • Anuria. (4, 5.2)
  • Severe hypovolemia. (4, 5.4)
  • Pre-existing severe pulmonary vascular congestion or pulmonary edema. (4, 5.5)
  • Active intracranial bleeding except during craniotomy. (4)
US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

Administration Instructions (2.1):

  • For intravenous infusion, preferably through a central venous catheter.
  • Prior to administration, evaluate renal, cardiac and pulmonary status and correct fluid and electrolyte imbalances. Recommended Dosage (2.2):
  • The dosage, concentration and rate of administration depend on the age, weight and condition of the patient, including fluid requirement, urinary output and concomitant therapy.
  • Reduction of Intracranial Pressure and Treatment of Cerebral Edema: 0.25 g/kg administered every 6 to 8 hours as an intravenous infusion over at least 30 minutes.
  • Reduction of Intraocular Pressure: 1.5 to 2 g/kg administered as a single dose intravenously over at least 30 minutes. Administer 60 to 90 minutes before surgery to achieve maximal effect.
2.1 Important Preparation and Administration Instructions

2.1 Important Preparation and Administration Instructions

  • Mannitol Injection is for intravenous infusion preferably through a central venous catheter [see Warnings and Precautions (5.6), Description (11)].
  • Prior to the administration of Mannitol Injection, evaluate renal, cardiac, and pulmonary status of the patient and correct fluid and electrolyte imbalances [see Dosage and Administration (2.2)].
  • Do not administer Mannitol Injection simultaneously with blood products or through the same administration set because of the possibility of pseduoagglutination or hemolysis. If it is essential that blood be given simultaneously, at least 20 mEq of sodium chloride should be added to each liter of mannitol solution to avoid pseudoagglutination.
  • Do not transfer Mannitol Injection into polyvinylchloride (PVC) bags; a white flocculent precipitate may form from contact with PVC surfaces.
  • Administer Mannitol Injection using an administration set with a filter to ensure against infusion of mannitol crystals. Preparation 1. Visually inspect the container before preparation and again before administration. Do not administer unless solution is clear, the container undamaged, and the fliptop vial seal intact. 2. Crystals may form in Mannitol Injection, especially if the solution is exposed to low temperatures. If crystallization occurs, warm the vial in water at 80°C and periodically shake vigorously to dissolve the crystals. Mannitol Injection may be autoclaved at 121°C for 20 minutes at 15 psi. Cool to body temperature or less before administering. Re-inspect Mannitol Injection for crystals prior to administration. Discard the solution if all the crystals cannot be dissolved. 3. Remove cover from fliptop vial and cleanse stopper with antiseptic before use. 4. Additives may be incompatible. Consult with pharmacist, if available. 5. For single use only; discard unused portion.
2.2 Recommended Dosage

2.2 Recommended Dosage Prior to administration of Mannitol Injection, evaluate renal, cardiac, and pulmonary status of the patient and correct fluid and electrolyte imbalances. The total dosage, concentration, and rate of administration depend on the age, weight, and condition of the patient being treated, including fluid requirement, electrolyte balance, serum osmolality, urinary output, and concomitant therapy.

The following outline of administration and dosage is only a general guide to therapy. Reduction of Intracranial Pressure and Treatment of Cerebral Edema Usually a maximum reduction in intracranial pressure can be achieved with a dose of 0.25 g/kg administered as an intravenous infusion over at least 30 minutes, which may be repeated every six to eight hours.

During and following infusion of Mannitol Injection, monitor fluid and electrolytes, serum osmolarity, and renal, cardiac, and pulmonary function. Discontinue Mannitol Injection if renal, cardiac, or pulmonary status worsens or CNS toxicity develops [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5)]. Reduction of Intraocular Pressure The recommended dosage is 1.5 to 2 g/kg as a single dose administered as an intravenous infusion over at least 30 minutes.

When used preoperatively, administer Mannitol Injection 60 to 90 minutes before surgery to achieve maximal reduction of intraocular pressure before operation.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations, pharmacokinetics)

8.6 Renal Impairment Patients with pre-existing renal disease, patients with conditions that put them at high risk for renal failure, or those receiving potentially nephrotoxic drugs or other diuretics, are at increased risk of renal failure with administration of mannitol. Evaluate the renal, cardiac, and pulmonary status of the patient and correct fluid and electrolyte imbalances prior to administration of Mannitol Injection [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5)].

Patients with Renal Impairment In patients with renal impairment, the elimination half-life of mannitol is prolonged. In a published study, in patients with renal impairment including acute renal failure and end stage renal failure, the elimination half-life of mannitol was estimated at about 36 hours, based on serum osmolarity. In patients with renal impairment on dialysis, the elimination half-life of mannitol was reduced to 6 and 21 hours during hemodialysis and peritoneal dialysis, respectively [see Use in Specific Populations (8.6), Overdosage (10)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Mannitol Injection is approved for use in the pediatric population for the reduction of intracranial and intraocular pressure. Studies have not defined the optimal dose of Mannitol Injection in the pediatric population. The safety profile for mannitol use in pediatric patients is similar to adults at dosages described in labeling.

However, pediatric patients less than two years of age, particularly preterm and term neonates, may be at higher risk for fluid and electrolyte abnormalities following administration of Mannitol Injection due to decreased glomerular filtration rate and limited ability to concentrate urine [see Warnings and Precautions (5.4)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Mannitol is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in elderly patients with impaired renal function. Evaluate the renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances prior to administration of Mannitol Injection [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5)].

Administration

2.1 Important Preparation and Administration Instructions • Mannitol Injection is for intravenous infusion preferably through a central venous catheter [see Warnings and Precautions (5.6) , Description (11) ] . • Prior to the administration of Mannitol Injection, evaluate renal, cardiac, and pulmonary status of the patient and correct fluid and electrolyte imbalances [see Dosage and Administration (2.2) ]. • Do not administer Mannitol Injection simultaneously with blood products or through the same administration set because of the possibility of pseduoagglutination or hemolysis. If it is essential that blood be given simultaneously, at least 20 mEq of sodium chloride should be added to each liter of mannitol solution to avoid pseudoagglutination. • Do not transfer Mannitol Injection into polyvinylchloride (PVC) bags; a white flocculent precipitate may form from contact with PVC surfaces. • Administer Mannitol Injection using an administration set with a filter to ensure against infusion of mannitol crystals. Preparation 1. Visually inspect the container before preparation and again before administration. Do not administer unless solution is clear, the container undamaged, and the fliptop vial seal intact. 2. Crystals may form in Mannitol Injection, especially if the solution is exposed to low temperatures. If crystallization occurs, warm the vial in water at 80°C and periodically shake vigorously to dissolve the crystals. Mannitol Injection may be autoclaved at 121°C for 20 minutes at 15 psi. Cool to body temperature or less before administering. Re-inspect Mannitol Injection for crystals prior to administration. Discard the solution if all the crystals cannot be dissolved. 3. Remove cover from fliptop vial and cleanse stopper with antiseptic before use. 4. Additives may be incompatible. Consult with pharmacist, if available. 5. For single use only; discard unused portion.

2.2 Recommended Dosage Prior to administration of Mannitol Injection, evaluate renal, cardiac, and pulmonary status of the patient and correct fluid and electrolyte imbalances. The total dosage, concentration, and rate of administration depend on the age, weight, and condition of the patient being treated, including fluid requirement, electrolyte balance, serum osmolality, urinary output, and concomitant therapy. The following outline of administration and dosage is only a general guide to therapy. Reduction of Intracranial Pressure and Treatment of Cerebral Edema Usually a maximum reduction in intracranial pressure can be achieved with a dose of 0.25 g/kg administered as an intravenous infusion over at least 30 minutes, which may be repeated every six to eight hours. During and following infusion of Mannitol Injection, monitor fluid and electrolytes, serum osmolarity, and renal, cardiac, and pulmonary function. Discontinue Mannitol Injection if renal, cardiac, or pulmonary status worsens or CNS toxicity develops [see Warnings and Precautions (5.2 , 5.3 , 5.4 , 5.5) ] . Reduction of Intraocular Pressure The recommended dosage is 1.5 to 2 g/kg as a single dose administered as an intravenous infusion over at least 30 minutes. When used preoperatively, administer Mannitol Injection 60 to 90 minutes before surgery to achieve maximal reduction of intraocular pressure before operation.

US FDA label

Dosage forms

Philippines

  • Solution for injection: 20 g/100 mL
  • Solution for iv infusion: 100 g/500 mL, 200 mg/mL
  • Solution for i.v. infusion: 200 mg/mL
  • Solution for i.v. injection: 200 mg/mL
  • Solution for intravenous infusion: 200 mg/mL
  • Solution for iv infusion solution for iv infusion: 20 mg/mL
  • Solution for iv injection: 20 mg/100 mL
  • W/v) solution for iv infusion: 20 mg/mL (20 %

Registered products in the Philippines

13 products registered with the Food and Drug Administration (FDA) Philippines list Mannitol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products13
Philippine FDA-registered products for Mannitol
Package insert
A.N.B. MannitolMannitol
20 mg/mL (20%w/v) Solution for IV InfusionPolypropylene Plastic Bottle x 100 mL, 250 mL, 500 mL
RxVAT-exempt
A.N.B. Laboratories Co. Ltd.Thailand
Optimum Trading
DR-XY35228
Dec 15, 2030
Axatol-20Mannitol
200 mg/mL (20% w/v) Solution for IV InfusionLDPE Bottle x 250 mL (Box of 1's)
RxVAT-exempt
Axa Parenterals LimitedIndia
Brady Pharma Inc.
DRP-10524
Oct 11, 2031
DiuretolMannitol
20g/100 mL (20%) Solution for Injection (IV)LDPE Bottle Sealed with White Round Dust Cap x 500 mL
RxVAT-exempt
Althea Pharma Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-11877
May 13, 2027
MannaMannitol
200 mg/mL (20% w/v) Solution for I.V. Injection100 mL LDPE Bottle (Box of 1’s)
RxVAT-exempt
Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India
Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4437
May 24, 2031
NoneMannitol
20 % Solution for Injection (IV)LDPE Bottle x 500 mL
RxVAT-exempt
Euro-Med Laboratories Phil., Inc.Philippines
—
DR-XY14730
Jan 27, 2029
NoneMannitol
20 g/100 mL (20% w/v) Solution for Injection (IV)Polypropylene Bag x 500 mL
RxVAT-exempt
Euro-Med Laboratories Phil., Inc.Philippines
—
DR-XY46729
Oct 14, 2029
None20% Mannitol
20 mg/100 mL Solution for IV InjectionUSP Type II Glass Bottles with rubber stopper and overseal x 250 mL and 500 mL
RxVAT-exempt
Euro-Med Laboratories Phil., Inc.Philippines
—
DR-672
Feb 9, 2030
NoneMannitol
200 mg/mL (20% w/v) Solution for I.V. InfusionLow Density Polyethylene (LDPE) plastic container with nipple head and translucent green colored cap x 500 mL
RxVAT-exempt
Amanta Healthcare Ltd.India
Endure Medical, Inc.
DR-XY37180
Dec 4, 2029
OsmofundinMannitol
20% Solution for I.V. InfusionLDPE Plastic Bottle x 500 mL
RxVAT-exempt
B. Braun Medical Industries Sdn. Bhd.Malaysia
B. Braun Medical Supplies, Inc.
DR-XY14429
May 14, 2029
RenimaxMannitol
200 mg/mL (20% w/v) Solution for Intravenous InfusionType II Clear Colorless Glass Bottle Colorless Glass Bottle x 500 mL (Net Content)
RxVAT-exempt
Jiangsu Pengyao Pharmaceutical Co., Ltd.China
Global PharmatradeTrader: Mecechem (Wuxi) Co., Ltd.
DR-XY44620
Jun 5, 2030
(no brand name)Mannitol
100g/500mL Solution for IV InfusionPolypropylene bottle x 500 mL with polypropylene cap
RxVAT-exempt
Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China
Sahar International Trading Inc.Trader: Betterway Pharmaceutical Group (HK) Limited
DR-XY48375
Sep 23, 2027
(no brand name)Mannitol
20 mg/mL (20% w/v) Solution for IV Infusion Solution For Iv InfusionPolypropylene bottle x 100 mL, 500 mL, 1 liter
RxVAT-exempt
Guizhou Tiandi Pharmaceutical Co., Ltd.China
AMB HK Enterprises, Inc.
DRP-18789
Sep 7, 2031
(no brand name)Mannitol
200 mg/mL (20 g/100mL) 20% w/v Solution for IV InfusionPolypropylene Bottle x 100 mL, 500 mL and 1 Liter
RxVAT-exempt
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Philrx Pharma Inc.
DRP-17264
Nov 4, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Mannitol Injection 25%, USP: 12.5 g/50 mL (0.25 g/mL) of mannitol as a clear and colorless solution in a single-dose vial. Mannitol Injection 25%, USP: 12.5 g/50 mL (0.25 g/mL) in a single-dose vial (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • • Hypersensitivity Reactions, Including Anaphylaxis: Stop infusion immediately if hypersensitivity reactions develop. (5.1)
  • • Renal Complications Including Renal Failure: Risk factors include pre-existing renal disease, conditions that put patients at risk for renal failure and concomitant use of nephrotoxic drugs or other diuretics. Avoid use of nephrotoxic drugs. Discontinue Mannitol Injection if renal function worsens. (5.2, 8.6)
  • • Central Nervous System (CNS) Toxicity: Confusion, lethargy, and coma may occur during or after infusion. Concomitant neurotoxic drugs may potentiate toxicity. Avoid use of neurotoxic drugs. Discontinue Mannitol Injection if CNS toxicity develops. (5.3)
  • • Fluid and Electrolyte Imbalances, Hyperosmolarity: Hypervolemia may exacerbate congestive heart failure; hyponatremia can lead to encephalopathy; hypo/hyperkalemia can result in cardiac adverse reactions in sensitive patients. Discontinue Mannitol Injection if fluid and/or electrolyte imbalances occur. (5.4)
  • • Monitoring/Laboratory Tests: Monitor fluid and electrolytes, serum osmolarity and renal, cardiac, and pulmonary function. Discontinue if toxicity develops. (5.5)
  • • Infusion Site Reactions: May cause irritation and inflammation, as well as severe reactions (compartment syndrome) when associated with extravasation. (5.6)
  • • Interference with Laboratory Tests: High …
5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis, hypotension, and dyspnea resulting in cardiac arrest and death have been reported with Mannitol Injection [see Adverse Reactions (6)]. Stop the infusion immediately if signs or symptoms of a suspected hypersensitivity reaction develop.

Initiate appropriate therapeutic countermeasures as clinically indicated.

5.2 Renal Complications Including Renal Failure

5.2 Renal Complications Including Renal Failure Renal complications, including irreversible renal failure, have been reported in patients receiving mannitol. Reversible, oliguric acute kidney injury has occurred in patients with normal pretreatment renal function who received large intravenous doses of mannitol. Although the osmotic nephrosis associated with mannitol administration is in principle reversible, osmotic nephrosis in general is known to potentially proceed chronic or even end-stage renal failure.

Monitor renal function closely, including signs of urine output reduction, during mannitol injection. Patients with pre-existing renal disease, patients with conditions that put them at risk for renal failure, or those receiving potentially nephrotoxic drugs or other diuretics, are at increased risk for renal failure following administration of Mannitol Injection.

Avoid concomitant administration of nephrotoxic drugs (e.g., aminoglycosides) or other diuretics with Mannitol Injection, if possible [see Drug Interactions (7)]. Patients with oliguric acute kidney injury who subsequently develop anuria while receiving mannitol are at risk of congestive heart failure, pulmonary edema, hypertensive crisis, coma, and death.

During and following infusion of Mannitol Injection for the reduction in intracranial pressure, monitor the patient clinically and laboratory tests for changes in fluid and electrolyte status. Discontinue Mannitol Injection if renal function worsens [see Warnings and Precautions (5.5)].

5.3 Central Nervous System (CNS) Toxicity

5.3 Central Nervous System (CNS) Toxicity CNS toxicity manifested by, e.g., confusion, lethargy, coma, has been reported in patients treated with mannitol, some resulting in death, in particular in the presence of impaired renal function CNS toxicity may result from high serum mannitol concentrations, serum hyperosmolarity resulting in intracellular dehydration within CNS, hyponatremia or other disturbances of electrolyte and acid/base balance secondary to mannitol administration [see Warnings and Precautions (5.4)]. At high concentrations, mannitol may cross the blood brain barrier and interfere with the ability of the brain to maintain the pH of the cerebrospinal fluid especially in the presence of acidosis.

In patients with pre-existing compromise of the blood brain barrier, the risk of increasing cerebral edema (general and focal) associated with repeated or continued use of Mannitol Injection must be individually weighed against the expected benefits. A rebound increase of intracranial pressure may occur several hours after the infusion.

Patients with a compromised blood brain barrier are at increased risk. Concomitant administration of neurotoxic drugs (e.g., aminoglycosides) with Mannitol Injection may potentiate neurotoxicity. Avoid concomitant use of neurotoxic drugs, if possible [see Drug Interactions (7.3)]. During and following infusion of Mannitol Injection for the reduction in intracranial pressure, monitor the patient clinically and laboratory tests for changes in fluid and electrolyte status.

Discontinue Mannitol Injection if CNS toxicity develops [see Warnings and Precautions (5.5)].

5.4 Fluid and Electrolyte Imbalances, Hyperosmolarity

5.4 Fluid and Electrolyte Imbalances, Hyperosmolarity Depending on dosage and duration, administration of Mannitol Injection may result in hypervolemia leading to or exacerbating existing congestive heart failure. Accumulation of mannitol due to insufficient renal excretion increases the risk of hypervolemia. Mannitol-induced osmotic diuresis may cause or worsen dehydration/hypovolemia and hemoconcentration.

Administration of Mannitol Injection may also cause hyperosmolarity [see Description (11)]. Depending on dosage and duration of administration, electrolyte and acid/base imbalances may also result from transcellular shifts in water and electrolytes, osmotic diuresis, and/or other mechanisms. Such imbalances may be severe and potentially fatal.

Imbalances that may result from administration of Mannitol Injection include:

  • Hypernatremia, dehydration, and hemoconcentration
  • Hyponatremia, which can lead to headache, nausea, seizures, lethargy, coma, cerebral edema, and death. Acute symptomatic hyponatremic encephalopathy is considered a medical emergency.
  • Hypo/hyperkalemia. The development of electrolyte imbalances (e.g., hyperkalemia, hypokalemia) associated with mannitol administration may result in cardiac adverse reactions in patients receiving drugs that are sensitive to such imbalances (e.g., digoxin, agents that may cause QT prolongation, neuromuscular blocking agents) [see Drug Interactions (7.4)].
  • Other electrolyte disturbances
  • Metabolic acidosis/alkalosis Pediatric patients less than two years of age, particularly preterm and term neonates, may be at higher risk for fluid and electrolyte abnormalities following administration of Mannitol Injection due to decreased glomerular filtration rate and limited ability to concentrate urine [see Use in Specific Populations (8.4)]. During and following infusion of Mannitol Injection for the reduction in intracranial pressure, monitor fluid and electrolyte status and discontinue Mannitol Injection if imbalances occur [see Warnings and Precautions (5.5)].
5.5 Monitoring/Laboratory Tests

5.5 Monitoring/Laboratory Tests During and following infusion of Mannitol Injection for the reduction in intracranial pressure, monitor:

  • serum osmolarity, serum electrolytes (including sodium, potassium, calcium and phosphate) and acid/base balance,
  • the osmol gap
  • signs of hypo- or hypervolemia, including urine output
  • renal, cardiac, and pulmonary function
  • intracranial pressure Discontinue Mannitol Injection if renal, cardiac, or pulmonary status worsens or CNS toxicity develops [see Contraindications (4)].
5.6 Infusion Site Reactions

5.6 Infusion Site Reactions The infusion of hypertonic solutions through a peripheral vein, including Mannitol Injection, may result in peripheral venous irritation, including phlebitis. Other severe infusion site reactions, such as compartment syndrome and swelling associated with extravasation, can occur with administration of Mannitol Injection [see Adverse Reactions (6)].

Mannitol Injection is preferably administered through a central venous catheter [see Dosage and Administration (2.1)].

5.7 Interference with Laboratory Tests

5.7 Interference with Laboratory Tests High concentrations of mannitol can cause false low results for inorganic phosphorus blood concentrations [see Drug Interactions (7.6)]. Mannitol may produce false positive results in tests for blood ethylene glycol concentrations [see Drug Interactions (7.6)].

Drug interactions

Drug interactions (US label) US FDA label
  • • Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2)
  • • Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3)
  • • Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4)
  • • Renally Eliminated Drugs: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5)
7.1 Nephrotoxic Drugs

7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., cyclosporine, aminoglycosides) increases the risk of renal failure following administration of mannitol. Avoid use of nephrotoxic drugs with Mannitol Injection, if possible [see Warnings and Precautions (5.2)].

7.2 Diuretics

7.2 Diuretics Concomitant administration of other diuretics may potentiate the renal toxicity of mannitol. Avoid concomitant administration of other diuretics with Mannitol Injection, if possible [see Warnings and Precautions (5.2)].

7.3 Neurotoxic Drugs

7.3 Neurotoxic Drugs Concomitant administration of systemic neurotoxic drugs (e.g., aminoglycosides) with Mannitol Injection may potentiate the CNS toxicity of mannitol. Avoid use of systemic neurotoxic drugs with Mannitol Injection, if possible [see Warnings and Precautions (5.3)].

7.4 Drugs Affected by Electrolyte Imbalances

7.4 Drugs Affected by Electrolyte Imbalances The development of electrolyte imbalances (e.g., hyperkalemia, hypokalemia) associated with mannitol administration may result in cardiac adverse reactions in patients receiving drugs that are sensitive to such imbalances (e.g., digoxin, drugs that prolong the QT interval, neuromuscular blocking agents) [see Warnings and Precautions (5.4)]. During and following infusion of Mannitol Injection, monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens [see Warnings and Precautions (5.5)].

7.5 Renally Eliminated Drugs

7.5 Renally Eliminated Drugs Mannitol therapy may increase the elimination, and decrease the effectiveness of treatment with, drugs that undergo significant renal elimination. Concomitant administration of mannitol with lithium may initially increase the elimination of lithium but may also increase the risk of lithium toxicity if patients develop hypovolemia or renal impairment.

In patients receiving lithium, consider holding lithium doses during treatment with Mannitol Injection. In patients requiring concomitant administration of lithium and Mannitol Injection, frequently monitor serum lithium concentrations and for signs of lithium toxicity.

7.6 Interference with Laboratory Tests

7.6 Interference with Laboratory Tests High concentrations of mannitol can cause false low results for inorganic phosphorus blood concentrations when an assay based on the conversion of phosphate (orthophosphate) to the phosphomolybdate complex is used. Mannitol may produce false positive results in tests for blood ethylene glycol concentrations in which mannitol is initially oxidized to an aldehyde.

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS The following adverse reactions associated with the use mannitol were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity reactions: Cardiac arrest, anaphylaxis, hypotension, dyspnea, hypertension, pyrexia, chills, sweating, cough, musculoskeletal stiffness, myalgia, urticaria/rash, pruritus, generalized pain, discomfort, nausea, vomiting, headache [see Warnings and Precautions (5.1)] Renal failure: Acute kidney injury, osmotic nephrosis, anuria, oliguria, urinary retention [see Warnings and Precautions (5.2)] CNS toxicity: Coma, seizures, confusion, lethargy, rebound increase in intracranial pressure, headache, dizziness [see Warnings and Precautions (5.3)] Fluid and electrolyte imbalances: Metabolic acidosis, dehydration (hypovolemia), hypervolemia, hyponatremia, hypernatremia, hyperkalemia, hypokalemia [see Warnings and Precautions (5.4)] Infusion site reactions: Venous thrombosis, thrombophlebitis extending from the site of injection, compartment syndrome and swelling associated with extravasation [see Warnings and Precautions 5.6)] Cardiac and respiratory disorders: Tachycardia, angina-like chest pain, congestive heart failure, pulmonary congestion, hypotension, edema, rhinitis Gastrointestinal disorders: Dryness of mouth, nausea, vomiting General disorders: Thirst Most common adverse reactions are hypersensitivity reactions, renal failure, CNS toxicity, hypo/hypervolemia, hypo/hypernatremia, hypo/hyperkalemia, and infusion site reactions. (6) To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Adverse reaction frequency tables (US label) US FDA label
Hypersensitivity reactions:Cardiac arrest, anaphylaxis, hypotension, dyspnea, hypertension, pyrexia, chills, sweating, cough, musculoskeletal stiffness, myalgia, urticaria/rash, pruritus, generalized pain, discomfort, nausea, vomiting, headache [see Warnings and Precautions (5.1)]
Renal failure:Acute kidney injury, osmotic nephrosis, anuria, oliguria, urinary retention [see Warnings and Precautions (5.2)]
CNS toxicity:Coma, seizures, confusion, lethargy, rebound increase in intracranial pressure, headache, dizziness [see Warnings and Precautions (5.3)]
Fluid and electrolyte imbalances:Metabolic acidosis, dehydration (hypovolemia), hypervolemia, hyponatremia, hypernatremia, hyperkalemia, hypokalemia [see Warnings and Precautions (5.4)]
Infusion site reactions:Venous thrombosis, thrombophlebitis extending from the site of injection, compartment syndrome and swelling associated with extravasation [see Warnings and Precautions 5.6)]
Cardiac and respiratory disorders:Tachycardia, angina-like chest pain, congestive heart failure, pulmonary congestion, hypotension, edema, rhinitis
Gastrointestinal disorders:Dryness of mouth, nausea, vomiting
General disorders:Thirst

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary The available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see Data) .No adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to maternal infusion of mannitol.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data Human Data Published literature reports the presence of mannitol in amniotic fluid when mannitol is administered to pregnant women during the third trimester of pregnancy.

Mechanism of action

12.1 Mechanism of Action Mannitol, when administered intravenously, exerts its osmotic diuretic effect as a solute of relatively small molecular size largely confined to the extracellular space. Mannitol hinders tubular reabsorption of water and enhances excretion of sodium and chloride by elevating the osmolarity of the glomerular filtrate.

This increase in extracellular osmolarity affected by the intravenous administration of mannitol will induce the movement of intracellular water to the extracellular and vascular spaces. This action underlies the role of mannitol in reducing intracranial pressure, intracranial edema, and intraocular pressure.

US FDA label

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The elimination half-life of mannitol is 0.5 to 2.5 hours Metabolism Only a relatively small amount of the mannitol dose is metabolized after intravenous administration to healthy subjects.

Excretion Mannitol is eliminated primarily via the kidneys in unchanged form.

Following intravenous administration, approximately 80% of an administered dose of mannitol is estimated to be excreted in the urine in 3 hours with lesser amounts thereafter.

Specific Populations Patients with Renal Impairment In patients with renal impairment, the elimination half-life of mannitol is prolonged.

In a published study, in patients with renal impairment including acute renal failure and end stage renal failure, the elimination half-life of mannitol was estimated at about 36 hours, based on serum osmolarity.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Distribution Mannitol distributes largely to the extracellular space within 20 to 40 minutes after intravenous administration. The volume of distribution of mannitol is approximately 17 L in adults. Elimination In subjects with normal renal function, the total clearance is 87 to 109 mL/minute. The elimination half-life of mannitol is 0.5 to 2.5 hours Metabolism Only a relatively small amount of the mannitol dose is metabolized after intravenous administration to healthy subjects.

Excretion Mannitol is eliminated primarily via the kidneys in unchanged form. Mannitol is filtered by the glomeruli, exhibits less than 10% of tubular reabsorption, and is not secreted by tubular cells. Following intravenous administration, approximately 80% of an administered dose of mannitol is estimated to be excreted in the urine in 3 hours with lesser amounts thereafter.

Specific Populations Patients with Renal Impairment In patients with renal impairment, the elimination half-life of mannitol is prolonged. In a published study, in patients with renal impairment including acute renal failure and end stage renal failure, the elimination half-life of mannitol was estimated at about 36 hours, based on serum osmolarity.

In patients with renal impairment on dialysis, the elimination half-life of mannitol was reduced to 6 and 21 hours during hemodialysis and peritoneal dialysis, respectively [see Use in Specific Populations (8.6), Overdosage (10)].

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Mannitol 20%, 500 mL Bottle₱58.78–₱320.00Reference ₱69.38per bottleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Mannitol
PNF listingInj.: 20%, 250 mL and 500 mL bottle (IV)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Mannitol · Hospira, Inc. [US FDA-approved label, version 23, April 21, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ad3145e-00e7-4412-b9a5-06f00f264f30
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .